XML 66 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaboration Agreements (Tables)
 12 Months Ended
Jan. 03, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Profits and losses on U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Profits and losses on U.S. commercialization
$
4,615

 
$
8,084

 
$
(2,140
)
Royalty revenues on ex-U.S. sales
$
5,679

 
$
5,564

 
$
6,398